Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.20 +1.0%	$19.28	$15.47 ▼ $36.37	$718.47M	1.47	187,710 shs	310,649 shs
CTMX CytomX Therapeutics	$2.52	$1.14	$0.40 ▼ $2.71	$203.17M	1.11	2.16 million shs	3.90 million shs
PHAR Pharming Group	$10.90 +8.7%	$8.95	$6.65 ▼ $11.07	$721.13M	-0.08	6,458 shs	907 shs
RCKT Rocket Pharmaceuticals	$2.48 -5.3%	$6.20	$2.19 ▼ $26.98	$264.83M	1.02	1.88 million shs	7.40 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+3.92%	+0.57%	-10.21%	+12.89%
CTMX CytomX Therapeutics	0.00%	+13.00%	+232.76%	+272.12%	+44.00%
PHAR Pharming Group	0.00%	+4.51%	+22.69%	+25.01%	+17.40%
RCKT Rocket Pharmaceuticals	0.00%	-60.45%	-68.45%	-73.76%	-88.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.2034 of 5 stars	3.6	0.0	0.0	2.8	0.0	0.0
CTMX CytomX Therapeutics	4.4634 of 5 stars	3.5	2.0	4.7	3.4	2.5	1.3
PHAR Pharming Group	2.5331 of 5 stars	3.5	5.0	0.0	2.0	0.0	0.6
RCKT Rocket Pharmaceuticals	4.7999 of 5 stars	4.2	2.0	4.7	2.1	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	85.31% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	111.64% Upside
PHAR Pharming Group	3.00	Buy	$30.00	175.36% Upside
RCKT Rocket Pharmaceuticals	2.44	Hold	$21.21	755.41% Upside

Current Analyst Ratings Breakdown

Latest CTMX, PHAR, AVBP, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
CTMX CytomX Therapeutics	$147.56M	1.38	N/A	N/A	($0.71) per share	-3.55
PHAR Pharming Group	$320.71M	2.31	$0.12 per share	91.82	$3.26 per share	3.34
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	14.82	N/A	N/A	10.96%	-41.47%	8.11%	8/7/2025 (Estimated)
PHAR Pharming Group	-$10.55M	-$0.20	N/A	363.17	N/A	-6.09%	-7.65%	-3.82%	7/30/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest CTMX, PHAR, AVBP, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/13/2025	Q4 2024	PHAR Pharming Group	$0.07	$0.05	-$0.02	$0.05	$76.67 million	$92.70 million
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
CTMX CytomX Therapeutics	N/A	1.04	1.04
PHAR Pharming Group	0.41	3.53	2.76
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CTMX CytomX Therapeutics	67.77%
PHAR Pharming Group	0.03%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
CTMX CytomX Therapeutics	7.00%
PHAR Pharming Group	2.07%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

CTMX, PHAR, AVBP, and RCKT Headlines

Recent News About These Companies

Leerink Partnrs Has Positive Forecast for RCKT Q2 Earnings

June 1 at 1:21 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Inline" at Evercore ISI

May 31 at 10:28 AM | marketbeat.com

Wedbush Raises Earnings Estimates for Rocket Pharmaceuticals

May 31 at 6:12 AM | marketbeat.com

Leerink Partnrs Has Positive Outlook of RCKT Q2 Earnings

May 31 at 5:52 AM | marketbeat.com

What is Lifesci Capital's Forecast for RCKT Q2 Earnings?

May 31 at 5:45 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI

May 31 at 5:44 AM | americanbankingnews.com

Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 31 at 3:28 AM | marketbeat.com

Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 31 at 3:02 AM | marketbeat.com

Wedbush Brokers Increase Earnings Estimates for RCKT

May 31 at 2:53 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $37.73 Consensus Target Price from Brokerages

May 31 at 2:53 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded to "Neutral" Rating by JPMorgan Chase & Co.

May 30 at 3:55 PM | marketbeat.com

RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now

May 30 at 11:00 AM | accessnewswire.com

Q2 Earnings Forecast for RCKT Issued By Lifesci Capital

May 30 at 7:51 AM | marketbeat.com

Leerink Partnrs Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Hold

May 30 at 7:49 AM | marketbeat.com

Toronto Dominion Bank Acquires New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 30 at 4:34 AM | marketbeat.com

Leerink Partners Reiterates Market Perform Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

May 30 at 3:35 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded by The Goldman Sachs Group to "Sell"

May 30 at 3:35 AM | americanbankingnews.com

JPMorgan Chase & Co. Reiterates Neutral Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

May 30 at 2:55 AM | americanbankingnews.com

BMO Capital Markets Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $8.00

May 30 at 2:23 AM | americanbankingnews.com

Scotiabank Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $19.00

May 30 at 2:23 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

May 29 at 6:44 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
By Leo Miller | May 22, 2025
View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
By Jeffrey Neal Johnson | May 29, 2025
View Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
By Leo Miller | May 6, 2025
View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

CTMX, PHAR, AVBP, and RCKT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$21.20 +0.20 (+0.95%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.26 +0.06 (+0.28%)

As of 05/30/2025 04:20 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CytomX Therapeutics NASDAQ:CTMX

$2.52 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.63 +0.11 (+4.21%)

As of 05/30/2025 07:55 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Pharming Group NASDAQ:PHAR

$10.90 +0.88 (+8.73%)

Closing price 05/30/2025 03:44 PM Eastern

Extended Trading

$11.16 +0.26 (+2.39%)

As of 05/30/2025 04:04 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 -0.14 (-5.34%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.49 +0.01 (+0.40%)

As of 05/30/2025 07:53 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time